145 related articles for article (PubMed ID: 25559205)
1. Cyclopentyl-pyrimidine based analogues as novel and potent IGF-1R inhibitor.
Aware V; Gaikwad N; Chavan S; Manohar S; Bose J; Khanna S; B-Rao C; Dixit N; Singh KS; Damre A; Sharma R; Patil S; Roychowdhury A
Eur J Med Chem; 2015 Mar; 92():246-56. PubMed ID: 25559205
[TBL] [Abstract][Full Text] [Related]
2. Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors.
Stauffer F; Cowan-Jacob SW; Scheufler C; Furet P
Bioorg Med Chem Lett; 2016 Apr; 26(8):2065-7. PubMed ID: 26951750
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).
Degorce SL; Boyd S; Curwen JO; Ducray R; Halsall CT; Jones CD; Lach F; Lenz EM; Pass M; Pass S; Trigwell C
J Med Chem; 2016 May; 59(10):4859-66. PubMed ID: 27078757
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.
Buchanan JL; Newcomb JR; Carney DP; Chaffee SC; Chai L; Cupples R; Epstein LF; Gallant P; Gu Y; Harmange JC; Hodge K; Houk BE; Huang X; Jona J; Joseph S; Jun HT; Kumar R; Li C; Lu J; Menges T; Morrison MJ; Novak PM; van der Plas S; Radinsky R; Rose PE; Sawant S; Sun JR; Surapaneni S; Turci SM; Xu K; Yanez E; Zhao H; Zhu X
Bioorg Med Chem Lett; 2011 Apr; 21(8):2394-9. PubMed ID: 21414779
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase.
Chamberlain SD; Wilson JW; Deanda F; Patnaik S; Redman AM; Yang B; Shewchuk L; Sabbatini P; Leesnitzer MA; Groy A; Atkins C; Gerding R; Hassell AM; Lei H; Mook RA; Moorthy G; Rowand JL; Stevens KL; Kumar R; Shotwell JB
Bioorg Med Chem Lett; 2009 Jan; 19(2):469-73. PubMed ID: 19056263
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor.
Bugge S; Kaspersen SJ; Larsen S; Nonstad U; Bjørkøy G; Sundby E; Hoff BH
Eur J Med Chem; 2014 Mar; 75():354-74. PubMed ID: 24556149
[TBL] [Abstract][Full Text] [Related]
7. Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.
Fairhurst RA; Marsilje TH; Stutz S; Boos A; Niklaus M; Chen B; Jiang S; Lu W; Furet P; McCarthy C; Stauffer F; Guagnano V; Vaupel A; Michellys PY; Schnell C; Jeay S
Bioorg Med Chem Lett; 2016 Apr; 26(8):2057-64. PubMed ID: 26951753
[TBL] [Abstract][Full Text] [Related]
8. Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening.
Liu X; Xie H; Luo C; Tong L; Wang Y; Peng T; Ding J; Jiang H; Li H
J Med Chem; 2010 Mar; 53(6):2661-5. PubMed ID: 20178321
[TBL] [Abstract][Full Text] [Related]
9. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
Tandon R; Kapoor S; Vali S; Senthil V; Nithya D; Venkataramanan R; Sharma A; Talwadkar A; Ray A; Bhatnagar PK; Dastidar SG
Eur J Pharmacol; 2011 Sep; 667(1-3):56-65. PubMed ID: 21640718
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
11. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents.
Steiner L; Blum G; Friedmann Y; Levitzki A
Eur J Pharmacol; 2007 May; 562(1-2):1-11. PubMed ID: 17376430
[TBL] [Abstract][Full Text] [Related]
12. Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity.
Chamberlain SD; Redman AM; Wilson JW; Deanda F; Shotwell JB; Gerding R; Lei H; Yang B; Stevens KL; Hassell AM; Shewchuk LM; Leesnitzer MA; Smith JL; Sabbatini P; Atkins C; Groy A; Rowand JL; Kumar R; Mook RA; Moorthy G; Patnaik S
Bioorg Med Chem Lett; 2009 Jan; 19(2):360-4. PubMed ID: 19071018
[TBL] [Abstract][Full Text] [Related]
13. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties.
Somakala K; Tariq S; Amir M
Bioorg Chem; 2019 Jun; 87():550-559. PubMed ID: 30928877
[TBL] [Abstract][Full Text] [Related]
15. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
16. Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine inhibitors of IGF-1R: elimination of an acid-mediated decomposition pathway.
Chamberlain SD; Redman AM; Patnaik S; Brickhouse K; Chew YC; Deanda F; Gerding R; Lei H; Moorthy G; Patrick M; Stevens KL; Wilson JW; Brad Shotwell J
Bioorg Med Chem Lett; 2009 Jan; 19(2):373-7. PubMed ID: 19081716
[TBL] [Abstract][Full Text] [Related]
17. Discovery of phenylpiperazine derivatives as IGF-1R inhibitor with potent antiproliferative properties in vitro.
Guo FJ; Sun J; Gao LL; Wang XY; Zhang Y; Qian SS; Zhu HL
Bioorg Med Chem Lett; 2015 Mar; 25(5):1067-71. PubMed ID: 25648298
[TBL] [Abstract][Full Text] [Related]
18. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
Lee W; Ortwine DF; Bergeron P; Lau K; Lin L; Malek S; Nonomiya J; Pei Z; Robarge KD; Schmidt S; Sideris S; Lyssikatos JP
Bioorg Med Chem Lett; 2013 Sep; 23(18):5097-104. PubMed ID: 23932790
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.
Patnaik S; Stevens KL; Gerding R; Deanda F; Shotwell JB; Tang J; Hamajima T; Nakamura H; Leesnitzer MA; Hassell AM; Shewchuck LM; Kumar R; Lei H; Chamberlain SD
Bioorg Med Chem Lett; 2009 Jun; 19(11):3136-40. PubMed ID: 19394223
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase.
Ducray R; Simpson I; Jung FH; Nissink JW; Kenny PW; Fitzek M; Walker GE; Ward LT; Hudson K
Bioorg Med Chem Lett; 2011 Aug; 21(16):4698-701. PubMed ID: 21775140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]